Lannett fails a second time on Zomig in US

Two US patents shielding Impax’ Zomig (zolmitriptan) nasal spray are not invalid, a US Court of Appeals has affirmed, upholding an unfavourable lower court ruling against abbreviated new drug application (ANDA) filer Lannett.